Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A1 | O00337 | 1/20 | 0.44 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.44 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.44 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.44 |
| ▸ | P2RY6 | Q15077 | 9/20 | 0.39 |
| ▸ | DUT | P33316 | 3/20 | 0.35 |
| ▸ | P2RY2 | P41231 | 2/20 | 0.34 |
| ▸ | P2RY4 | P51582 | 2/20 | 0.34 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.34 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26289942 | 0.89 | P2RY6 (0.39) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL51723 | 0.84 | SLC28A1 (0.45) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL28786348 | 0.84 | SLC28A1 (0.45) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL27577710 | 0.83 | SLC28A1 (0.43) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL27500199 | 0.83 | SLC28A1 (0.43) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL25303152 | 0.83 | SLC28A1 (0.43) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL516166 | 0.83 | SLC28A1 (0.43) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL65485 | 0.82 | SLC28A1 (0.44) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL2242410 | 0.82 | SLC28A1 (0.44) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL414705 | 0.82 | SLC28A1 (0.44) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106117287-A | The method preparing 5-methyl deoxyuridine | 上海艾美晶生物科技有限公司 | 2016-11-16 | — | — | CN | claimed |
| JP-2584947-B2 | — | — | 1997-02-26 | — | — | JP | claimed |
| WO-1996040165-A1 | METHODS OF REDUCING TOXICITY OF CHEMOTHERAPEUTIC AND ANTIVIRAL AGENTS WITH ACYLATED PYRIMIDINE NUCLEOSIDES | PRO-NEURON, INC. (US) | 1996-12-19 | — | — | WO | claimed |
| EP-0594667-A4 | TREATMENT OF CHEMOTHERAPEUTIC AGENT AND ANTIVIRAL AGENT TOXICITY WITH ACYLATED PYRIMIDINE NUCLEOSIDES | PRO NEURON INC (US) | 1996-01-10 | — | — | EP | claimed |
| EP-0594667-A1 | TREATMENT OF CHEMOTHERAPEUTIC AGENT AND ANTIVIRAL AGENT TOXICITY WITH ACYLATED PYRIMIDINE NUCLEOSIDES | PRO-NEURON, INC. (US) | 1994-05-04 | — | — | EP | claimed |
| WO-1993001202-A1 | TREATMENT OF CHEMOTHERAPEUTIC AGENT AND ANTIVIRAL AGENT TOXICITY WITH ACYLATED PYRIMIDINE NUCLEOSIDES | PRO-NEURON, INC. (US) | 1993-01-21 | — | — | WO | claimed |
| WO-2025101722-A1 | HIGH-AFFINITY ENGINEERED CHROMODOMAINS | AXOIYA INC. (US) | 2025-05-15 | — | — | WO | disclosed |
| WO-2025064825-A1 | DNA LIGASE COMPOSITIONS, METHODS, AND USES THEREOF | REVISION BIO CORPORATION (US) | 2025-03-27 | — | — | WO | disclosed |
| WO-2025064811-A1 | DNA-DEPENDENT DNA POLYMERASE COMPOSITIONS, METHODS, AND USES THEREOF | REVISION BIO CORPORATION (US) | 2025-03-27 | — | — | WO | disclosed |
| CN-119317714-A | Nucleic acid modified biological cells with amplification-dependent gene expression | 蒂宾根大学医学院 | 2025-01-14 | — | — | CN | disclosed |
| CN-112805386-B | Plasmid containing a sequence encoding mRNA having a segmented poly (A) tail | 埃泽瑞斯公司 | 2024-12-03 | — | — | CN | disclosed |
| EP-4399307-A2 | HBB-MODULATING COMPOSITIONS AND METHODS | Flagship Pioneering Innovations VI, LLC (US) | 2024-07-17 | — | — | EP | disclosed |
| CN-117729930-A | Use of IFN-lambda mRNA for the treatment of viral infections | 埃泽瑞斯公司 | 2024-03-19 | — | — | CN | disclosed |
| WO-1996040165-A1 | METHODS OF REDUCING TOXICITY OF CHEMOTHERAPEUTIC AND ANTIVIRAL AGENTS WITH ACYLATED PYRIMIDINE NUCLEOSIDES | PRO-NEURON, INC. (US) | 1996-12-19 | — | — | WO | disclosed |
| EP-0746336-A1 | PRODRUGS ACTIVATED BY TARGETED CATALYTIC PROTEINS | IGEN, INC. (US) | 1996-12-11 | — | — | EP | disclosed |
| EP-0746336-A4 | PRODRUGS ACTIVATED BY TARGETED CATALYTIC PROTEINS | IGEN INC (US) | 1996-07-26 | — | — | EP | disclosed |
| EP-0594667-A4 | TREATMENT OF CHEMOTHERAPEUTIC AGENT AND ANTIVIRAL AGENT TOXICITY WITH ACYLATED PYRIMIDINE NUCLEOSIDES | PRO NEURON INC (US) | 1996-01-10 | — | — | EP | disclosed |
| EP-0594667-A1 | TREATMENT OF CHEMOTHERAPEUTIC AGENT AND ANTIVIRAL AGENT TOXICITY WITH ACYLATED PYRIMIDINE NUCLEOSIDES | PRO-NEURON, INC. (US) | 1994-05-04 | — | — | EP | disclosed |
| WO-1993002703-A1 | PRODRUGS ACTIVATED BY TARGETED CATALYTIC PROTEINS | IGEN, INC. (US) | 1993-02-18 | — | — | WO | disclosed |
| WO-1993001202-A1 | TREATMENT OF CHEMOTHERAPEUTIC AGENT AND ANTIVIRAL AGENT TOXICITY WITH ACYLATED PYRIMIDINE NUCLEOSIDES | PRO-NEURON, INC. (US) | 1993-01-21 | — | — | WO | disclosed |